Current approach to sinusitis by du Plessis, DJ
One of the most common infectious diseases encountered by medical practition-
ers is respiratory tract infection.  Most are caused by viruses and are called viral
rhinosinusitis (VRS).  The average child will suffer 3 - 8 and the average adult 2 -
3 episodes of VRS per year.  Bacterial infections complicate only about 0.5 - 2%
of these viral infections.  The dilemma that we are facing is that it is very often
virtually impossible to distinguish between the two.  This leads to the diagnosis of
bacterial sinusitis being made too often and patients are prescribed an antibiotic
that is not only ineffective against the viral disease, but also leads to the develop-
ment of bacterial resistance to the antibiotic.1 Very often antibiotics are used
against bacterial infections without taking their efficacy against the specific
pathogens into consideration.  This leads to treatment failure and the possibility
of complications of bacterial sinusitis.   It is therefore imperative that we do our
utmost to make the correct diagnosis and choose the correct antibiotic therapy.
ACUTE SINUSITIS
Acute sinusitis is a bacterial infection of one or more of the paranasal sinuses.  It
should rather be called acute bacterial rhinosinusitis (ABRS) because it rarely
occurs without concurrent rhinitis.2
Pathophysiology
Sinusitis is initiated by impairment of normal drainage and aeration of the sinus-
es, i.e. obstruction of the sinus ostia.  The most common cause is inflammation
caused by a preceding VRS.  Other causes are listed in Table I.3 Certain condi-
tions predispose individuals to sinusitis (Table II).  Inflammation causes increased
secretions and oedema of the sinonasal mucosa.  This in turn leads to obstruction
of the sinus ostia.  Secretions are retained due to the obstruction as well as cil-
iary dysfunction and the antigravitational placement of the ostia, particularly that
of the maxillary antrum.  Thus a favourable environment for bacterial growth is
created.  The most common area affected is the osteomeatal complex that is the
communal drainage area of the frontal, maxillary and anterior ethmoid sinuses
(Fig. 1).  Sinusitis may also result from local spread of particularly a dental infec-
tion.
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CURRENT APPROACH TO SINUSITIS
Sinusitis is one of the most common upper respiratory tract infections presenting in
general practice.
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The most common bacterial isolates
from the maxillary sinuses of patients
with ABRS are Streptococcus pneumo-
niae, Haemophilus influenzae and
Moraxella catarrhalis.  In a small per-
centage of cases other streptococcal
species, anaerobic bacteria and
Staphylococcus aureus are found.4
Although fungal elements are present
in the noses of many patients with
sinonasal problems, the clinical signifi-
cance in immunocompetent hosts is not
completely clear. 
Diagnosis of ABRS
Patients with VRS usually present with
a combination of the following symp-
toms: sneezing, rhinorrhoea, nasal
congestion, hyposmia/anosmia, facial
pressure, postnasal drip, sore throat,
cough, ear fullness, fever and myal-
gia.  After a few days of a viral infec-
tion the nasal secretions will become
mucopurulent due to an influx of neu-
trophils.  A change of colour of nasal
secretions is thus not a specific sign of
bacterial infection.
Clinical judgment is needed to decide
whether a bacterial infection is pres-
ent.  The symptoms associated with
ABRS include those typical of a viral
infection, but are usually more severe
and protracted.  A diagnosis of ABRS
may be made in a patient with a VRS
that has not improved after 10 days or
worsens after 5 - 7 days accompanied
by the typical symptoms listed in Table
III.  Examination reveals nasal conges-
tion and discharge, with purulence at
the specific sinus ostia on endoscopy.
There is also more localised tender-
ness over the affected sinuses.
Specific findings of a bacterial infec-
tion, like fever, facial erythema,
swelling and severe pain might also
be present.1
Physical examination thus provides lim-
ited information in the diagnosis of
ABRS and is open to individual inter-
pretation.  Transillumination of the
sinuses is unreliable.  Ultrasonography
can only assess the maxillary sinus
and cannot distinguish between viral
and bacterial sinusitis and so has limit-
ed utility.  X-ray examination of the
sinuses can demonstrate opacification
and fluid levels in the maxillary,
frontal and sphenoid sinuses, but does
not visualise the ethmoids well and
does not determine the extent of the
disease.3 A negative radiograph does
however have diagnostic value.1 CT
scans will clearly demonstrate abnor-
malities within the sinuses but are not
specific for bacterial disease.  The
majority of patients with VRS will have
abnormalities of the sinuses on CT
scan and MRI that will clear up with-
out any treatment,5 so these investiga-
tions are not indicated in uncomplicat-
ed cases of ABRS.1
Positive cultures from sinus aspirates
are the gold standard in the diagnosis
of ABRS.4 This is however invasive
and requires special skills and equip-
ment and is not indicated in uncompli-
cated cases.  Cultures from nasal and
nasopharyngeal swabs do not corre-
late with the bacteriology of cultures
from sinus aspirates and are therefore
not recommended.6 Endoscopic mid-
dle meatal cultures correlate better
and can be performed in selected
cases when the necessary equipment
is available.4,7
Treatment of ABRS
Acute sinusitis may be thought of as
an abscess.  Treatment should be
aimed at providing adequate
drainage and eradication of local
infection.  In most patients drainage
can be accomplished medically.
Topical vasoconstrictors (for less than
7 days), systemic decongestants and
mucolytics often provide adequate
drainage.  Saline irrigation of the
nose and steam inhalation are very
helpful.  Bacterial eradication is the
ultimate aim of treatment and this can
only be accomplished by adequate
antibiotic therapy.  The decision to
give antibiotics should not be taken
lightly, to prevent both over-treatment
of patients with viral infection and
future antimicrobial resistance.  The
less than satisfactory clinical diagnosis
of ABRS puts the practitioner under a
lot of pressure as patients are often
very demanding.  Furthermore we are
faced with the possible complications
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Fig. 1. Ostiomeatal complex pattern
of sinusitis. Ostiomeatal complex in
left middle meatus (*) obstructed by
inflammation, resulting in opacifica-
tion of the frontal (F), maxillary (M)
and anterior ethmoid (arrow) sinuses.
Table III. Symptoms associated with bacterial rhinosinusitis
Nasal drainage (purulent)
Nasal congestion










Some/all of above in patient with viral rhinosinusitis that has not
improved after 10 days or worsens after 5 - 7 days
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of untreated sinusitis.  The diagnosis
of ABRS and therefore the need for
antibiotic therapy can usually be made
in patients with the following clinical
picture: purulent nasal discharge, max-
illary tooth or facial pain (especially
when unilateral), unilateral or bilateral
sinus tenderness for 7 - 10 days or
worsening symptoms after initial
improvement (Table IV).
Because cultures of the sinuses are
rarely obtained, the organisms that
are present in a geographical area
and the patterns of resistance of these
organisms should be considered when
selecting an antibiotic (Table V).4,8
It is important for an antibiotic to pro-
vide adequate cover against S. pneu-
moniae due to the possibility of seri-
ous intracranial and extra-sinus compli-
cations.8 Gram-negative cover against
H. influenzae and M. catarrhalis is
also important.  Antibiotics should also
achieve an adequate concentration in
the mucus of the infected sinus to be
able to fight the infection.  The follow-
ing points should be noted:1
• Amoxicillin: considered the most
active oral B-lactam against strepto-
cocci.  Reaches high concentrations
in the sinuses.  Intermediate resist-
ance may be overcome to a large





lanate enhances amoxicillin’s activi-
ty against B-lactamase-producing
Gram-negatives but has no effect
on the activity against drug-resist-
ant S. pneumoniae — one can also
increase amoxicillin dose to over-
come this.  Active against anaer-
obes.  Twice daily dosing not
exceeding 10 mg/kg clavulanate
per day reduces gastrointestinal
side-effects.
• Cephalosporins: oral agents are
not effective against penicillin-resist-
ant S.  pneumoniae.  Cefuroxime
and cefpodoxime are very effective
against H. influenzae.  Only par-
enteral agents achieve high con-
centrations in the sinus cavity.
• Lincosamides (clindamycin):
excellent coverage against S. pneu-
moniae as well as many anaerobes
but no activity against H. influen-
zae or M. catarrhalis.
• Macrolides: ineffective against
penicillin-resistant pneumococci.
Selection of class resistance against
macrolides is a problem. In vivo
effectiveness against H. influenzae
is doubtful.
• Fluoroquinolones: newer
quinolones very effective against
respiratory pathogens in vitro.  In
vivo success probably not as good.
Emergence of class resistance has
been a problem in certain areas,
thus not for first-line therapy unless
allergic to penicillin.  Ciprofloxacin
does not provide adequate pneu-
mococcal cover and is not recom-
mended.  Currently not approved
for use in children.
• Ketolides: show promise of hav-
ing a low potential to select for
resistance.  Active against most
pathogens implicated in URTI.
Recent antibiotic therapy puts the
patient at risk of carrying resistant
organisms and thus affects the choice
and dosage of the antibiotic chosen to
treat the current infection.8 The pre-
dicted efficacy of antibiotics using a
mathematical model of ABS is as fol-
lows:1,8
Adults:
• > 90% (amoxicillin-clavulanate, gat-
ifloxacin, levofloxacin and moxi-
floxacin)
• 80 - 90% (high-dose amoxacillin,
cefuroxime axetil, cefpodoxime
proxetil)
• 70 - 80% (clindamycin (Gram +),
cefprozil, azithromycin and clar-
ithromycin)
• 50 - 60% (cefachlor, loracarbef).
Children:
• > 90% (amoxicillin-clavulanate,
high-dose amoxicillin)
• 80 - 90% (cefuroxime axetil, cefpo-
doxime proxetil, clindamycin
(Gram +), azithromycin and clar-
ithromycin)
• 70 - 80% (cefproxil)
• 60 - 70% (cefachlor, loracarbef).
The predicted spontaneous resolution
rate for untreated bacterial sinusitis 
Table IV. Diagnosis of ABRS and the need for antibiotic 
therapy
Purulent nasal discharge
Maxillary tooth or facial pain
Unilateral/bilateral sinus tenderness
Above symptoms for 7 - 10 days or worsening after initial improvement
Table V. Susceptibility of S. pneumoniae in URTI in SA
Johannesburg Pretoria Durban
Number of isolates 626 312 207
Penicillin
Susceptible 40% 35% 64%
Intermediate resistant 55% 64% 32%
Highly resistant 5% 1% 1%
Macrolides
Susceptible 46% 48% 53%
3rd generation cephalosporins
Susceptible 93% 95% 97%
Intermediate resistant 5% 5% 0%
Highly resistant 2% 0% 3%
Quinolones
Susceptible 100% 100% 99%
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varies from 46.6% in adults to 49.6%
in children.
The current recommended antibiotic
therapy for adults and children with
sinusitis is outlined in Tables VI and
VII.7 In summary one can say high-
dose amoxicillin will cure most pneu-
mococcal infections.  If treatment fails
the infection is most probably due to a
beta-lactam producing H. influenzae.
The addition of clavulanate is the first
choice in these cases due to the high
concentrations that it reaches in the
sinus cavity and its activity against
anaerobes.  In penicillin-allergic
patients quinolones are indicated.  The
recommended duration of antibiotic
therapy is 10 - 14 days.1,3,8 In select-
ed cases a longer course of therapy
might be indicated.
When the infection continues to wors-
en in spite of appropriate antibiotic
therapy or when a complication devel-
ops, surgical drainage of the affected
sinuses is indicated.  A number of
techniques are available to the sur-
geon:
• maxillary sinus: antral washout with
trocar via canine fossa or inferior
meatus
• frontal sinus: endoscopic or exter-
nal trephination
• ethmoid or sphenoid sinus: endo-
scopic or external spheno-eth-
moidectomy.
Complications of ABRS
Orbital complications are the most
common complication of sinusitis.
The Chandler classification gives a
clinical approach to orbital inflamma-
tion:
• inflammatory oedema (lid oedema)
• orbital cellulitis (diffuse oedema)
• subperiosteal abscess (displace-
ment of globe inferolaterally) (Fig.
2)
• orbital abscess (proptosis, chemo-
sis, ophthalmoplegia, decreased
vision)
• cavernous sinus thrombosis (bilater-
al eye findings, meningismus).
Patients with orbital signs need urgent
referral to an ENT specialist as well as
CT scan and possibly MRI evaluation.
Surgery is indicated for non-responsive
cellulitis and for any abscess or loss of
visual acuity.
Cavernous sinus thrombosis
might be difficult to differentiate from
orbital cellulitis or abscess.  The most
important signs are bilateral orbital
involvement, rapidly progressive
chemosis and ophthalmoplegia, severe
retinal engorgement and high fever.
The condition has a high mortality.
Treatment includes intravenous antibi-
otics, drainage of abscess and orbital
decompression.
Osteomyelitis of the frontal bone
might lead to a subperiosteal abscess
or Pott’s puffy tumour (Fig. 3).  Sinus
trephination with or without drainage
of the abscess and antibiotics is indi-
cated.
Table VI. First-line antibiotic recommendations for ABS1,8
Adults
First-line therapy (oral)
• Amoxicillin 1.5 - 3.5 g/day
• Patients with no prior antibiotic use
• Amoxicillin 3 - 3.5 g/day
* Areas with high incidence of penicillin-resistant
pneumococci
• Patients who received antibiotics during previous
month
• Beta-lactamase-stable antibiotics





If no improvement after 72 hours: proceed to second-line therapy or refer for further evaluation.
Children
First-line therapy (oral)
• Amoxicillin 40 - 50 mg/kg/day
• Patients with no prior antibiotic use
• Areas with low resistance
• Amoxicillin 90 mg/kg/day
• Areas with high incidence of penicillin-resistant
pneumococci
• Patients who received antibiotics during previous
month
• Beta-lactamase-stable antibiotics
• Children less than 2 years
• Immunocompromised patients
• Areas with high prevalence of beta-lactamase- 
producing bacteria
Fig. 2. Subperiosteal abscess.
Fig. 3. Osteomyelitis of the frontal
bone with abscess formation.







Patients suffering from bacterial sinusi-
tis who present with meningismus,
severe headache, intractable vomiting
and deteriorating levels of conscious-
ness should be hospitalised and inves-
tigated for possible intracranial com-
plication.
Mucoceles might develop long after
the acute episode of sinusitis and are
characterised by slow growth.  The
presentation varies depending on the
origin of the mucocele.  Progressive
proptosis is a common feature (Fig. 4).
Surgery is usually indicated.
CHRONIC SINUSITIS
There is no generally accepted defini-
tion of chronic sinusitis.  Signs and
symptoms of sinus inflammation per-
sisting after 8 weeks or several recur-
rent episodes of acute sinusitis within
a short time frame may be considered
chronic.3,6 The cause of chronic sinusi-
tis may fall into one of 4 categories:
• inadequately treated acute sinusitis
• anatomical obstruction of sinus
ostia
• pathology of local mucociliary
defence mechanism such as cystic
fibrosis
• systemic immune problem such as
allergic rhinitis.
It is therefore imperative that the infec-
tion has been adequately managed
medically and that a thorough search
has been undertaken for an underlying
aetiological factor.  When all systemic
factors have been excluded, the treat-
ment of chronic sinusitis should include
the following: antibiotics for 4 weeks
with a second-line antibiotic that pro-
vides anaerobic cover or in combina-
tion with metronidazole or clin-
damycin.3 Intranasal corticosteroid
sprays and decongestants should also
be used.  If a patient fails to respond
to medical management or if a clear
anatomical reason for obstruction of
the sinus exists, surgery is indicated.
Sinus drainage with endoscopic
approach, sometimes combined with
septal surgery, is usually effective.
Repeated antral lavage is not indicat-
ed as the maxillary sinus is not the
focus of the pathology.3
SINUSITIS IN CHILDREN
The paranasal sinuses are incomplete-
ly developed in children.  At birth the
maxillary sinus is only a small air cell
and the ethmoid sinuses are only
beginning to develop.  The frontal
sinus does not develop until the age of
6 - 8 years.  All the sinuses continue
to develop well into adolescence.6
This makes interpretation of signs and
symptoms in children presenting with
URTI difficult.  An URTI associated with
pus draining from the middle meatus
and pain indicates ABRS.  Halitosis, 
Fig. 4. Mucocele of the ethmoid
labyrinth.




• Amoxicillin/clavulanate (high dose amoxicillin)
• Cefuroxime axetil 1 g bd
• Cefpodoxime proxetil 200 mg bd
• Fluoroquinolones
• Patients intolerant to or recently not responding
to beta-lactamase-stable antibiotics
• Azithromycin/clarithromycin 500 mg/day for 10
days
• Only beta-lactam-allergic patients
• Clindamycin 150 mg qid
• Beta-lactam-allergic patients
• Confirmed pneumococcal infection unresponsive
to beta-lactams
• May be used in combination with antibiotics
with a good Gram-negative cover
Third-line therapy
• Fluoroquinolones




• Amoxicillin/clavulanate with amoxicillin dose of
90 mg/kg/day
• Cefuroxime axetil 30 mg/kg/day
• Cefpodoxime proxetil 8 - 16 mg/kg/d
• Azithromycin 10 mg/kg/day or clarithromycin 15
mg/kg/day for 10 days
• Only beta-lactam-allergic patients
• Clindamycin 17 - 25 mg/kg/day
• Beta-lactam-allergic patients
• Confirmed pneumococcal infection unresponsive
to beta-lactams
• May be used in combination with antibiotics
with a good Gram-negative cover 
Third-line therapy
• Ceftriaxone 50 mg/kg/d for 3 - 5 days
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The average child will suf-
fer 3 - 8 and the average
adult 2 - 3 episodes of VRS
per year.  Bacterial infec-
tions complicate only about
0.5 - 2% of these viral
infections.
Very often antibiotics are
used against bacterial
infections without taking
their efficacy against the
specific pathogens into
consideration.
Sinusitis is initiated by
impairment of normal
drainage and aeration of
the sinuses, i.e. obstruction
of the sinus ostia.
Patients with VRS usually
present with a combination




sure, postnasal drip, sore
throat, cough, ear fullness,
fever and myalgia.
daytime cough, nasal obstruction, rhin-
orrhoea and fever are usually
present.3,6 The antibiotic guidelines are
outlined in Table VI.  Most children
will respond to amoxicillin.
Attendance in a day-care centre,
severe disease and failure to improve
after 3 days of therapy argue for the
use of high-dose amoxicillin-clavu-
lanate.  If this fails, intravenous ceftri-
axone might be indicated.  In children
with penicillin allergy a macrolide or
clindamycin should be given.  These
drugs are however not effective
against H. influenzae or penicillin-
resistant pneumococci.  Surgery is
indicated for failed medical therapy or
suppurative complications.  Surgery
for chronic sinusitis remains controver-
sial.  Patients should first be investigat-
ed and treated for systemic problems
such as allergy, asthma, cystic fibrosis
and immune deficiencies such as IgA
or IgG deficiency.  When surgery is
indicated, it should be limited.  The
following are indications for surgery:
• spread of disease to adjacent struc-
tures
• sinus disease aggravating underly-
ing condition such as asthma or
cystic fibrosis
• definite areas of anatomic obstruc-
tion that can be linked to sinus dis-
ease.
FUNGAL SINUSITIS
The management of patients with fun-
gal sinusitis falls outside the scope of
this article, but surgery plays a major
role in the management of most
patients.
Fungal sinusitis can be categorised as
follows:
• invasive — fulminant or chronic
indolent
• non-invasive — mycetoma (fungus
ball) or saprophytic
• allergic fungal sinusitis.
Patients with allergic fungal sinusitis
usually present with nasal polyposis.
There is a feeling among some
researchers that fungi may play a role
in all patients with nasal polyps.
Currently it would be unwise to
assume this, but future research will
hopefully shed some light on this mat-
ter.
References available on request.
Most URTIs are viral infections.
Only 0.5 - 2% of viral URTIs are




Moraxella catarrhalis are the most
common bacterial isolates.
The diagnosis of ABRS is usually
made on clinical judgment.
The organisms most commonly
encountered, as well as the patterns
of resistance in a geographical
area, should be taken into consider-
ation when selecting an antibiotic.
Antibiotic therapy should be given
for at least 10 days.
High-dose amoxicillin will cure most
sinus infections.
The addition of clavulanate will
extend cover to include most beta-
lactam-producing Gram-negative as
well as anaerobic bacteria.
IN A NUTSHELL
